Business
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:\n\n\nBofA Securities 2023 Health Care Conference\nFireside Chat: Wednesday, May 10, 2023 at 2:20 p.m. Eastern Time in Las Vegas, NV\n\n\nThe JMP Securities Life Sciences Conference\nFireside Chat: Tuesday, May 16, 2023 at 2:30 p.m. Eastern Time in New York, NY\n\n\n2023 RBC Capital Markets Global Healthcare Conference\nFireside Chat: Wednesday, May 17, 2023 at 1:35 p.m. Eastern Time in New York, NY\n\n\nLive webcasts of the presentations will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.\n\n\nAbout Acadia Pharmaceuticals\n\n\nAcadia is advancing breakthroughs in neuroscience to elevate life. For almost 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230502005329/en/\n\nMedia Contact:\nAcadia Pharmaceuticals Inc.\nDeb Kazenelson\n(818) 395-3043\[email protected]\n\n\nInvestor Contact:\nAcadia Pharmaceuticals Inc.\nMark Johnson, CFA\n(858) 261-2771\[email protected]\n\n\nSource: Acadia Pharmaceuticals Inc.","length":4316,"tagName":"div"}]